- Home
- CNTX vs CGEN Comparison
CNTX vs CGEN Comparison
Compare CNTX & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- CGEN
- Stock Information
- Founded
- CNTX 2015
- CGEN 1993
- Country
- CNTX United States
- CGEN Israel
- Employees
- CNTX N/A
- CGEN N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTX Health Care
- CGEN Health Care
- Exchange
- CNTX Nasdaq
- CGEN Nasdaq
- Market Cap
- CNTX 149.2M
- CGEN 158.5M
- IPO Year
- CNTX 2021
- CGEN 2000
- Fundamental
- Price
- CNTX $2.32
- CGEN $1.83
- Analyst Decision
- CNTX Strong Buy
- CGEN Strong Buy
- Analyst Count
- CNTX 3
- CGEN 2
- Target Price
- CNTX $6.50
- CGEN $4.00
- AVG Volume (30 Days)
- CNTX 78.6K
- CGEN 274.0K
- Earning Date
- CNTX 08-07-2024
- CGEN 08-06-2024
- Dividend Yield
- CNTX N/A
- CGEN N/A
- EPS Growth
- CNTX N/A
- CGEN N/A
- EPS
- CNTX N/A
- CGEN N/A
- Revenue
- CNTX N/A
- CGEN $42,720,000.00
- Revenue This Year
- CNTX N/A
- CGEN $18.69
- Revenue Next Year
- CNTX N/A
- CGEN N/A
- P/E Ratio
- CNTX N/A
- CGEN N/A
- Revenue Growth
- CNTX N/A
- CGEN 469.60
- 52 Week Low
- CNTX $0.77
- CGEN $0.53
- 52 Week High
- CNTX $2.75
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- CNTX 44.78
- CGEN 46.92
- Support Level
- CNTX $2.41
- CGEN $1.85
- Resistance Level
- CNTX $2.55
- CGEN $2.10
- Average True Range (ATR)
- CNTX 0.12
- CGEN 0.12
- MACD
- CNTX -0.04
- CGEN -0.01
- Stochastic Oscillator
- CNTX 26.35
- CGEN 16.67
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.